Extending a systems model of the APP pathway: Separation of β-and γ-secretase sequential cleavage steps of APP
EMT van Maanen, TJ van Steeg, MJ Ahsman… - … of Pharmacology and …, 2018 - ASPET
The abnormal accumulation of amyloid-β (Aβ) in the brain parenchyma has been posited as
a central event in the pathophysiology of Alzheimer’s disease. Recently, we have proposed …
a central event in the pathophysiology of Alzheimer’s disease. Recently, we have proposed …
[HTML][HTML] Experiences of Dutch maternity care professionals during the first wave of COVID-19 in a community based maternity care system
ELM van Manen, M Hollander, E Feijen-de Jong… - PloS one, 2021 - journals.plos.org
Background and objective During the COVID-19 pandemic the organization of maternity
care changed drastically; this study into the experiences of maternity care professionals with …
care changed drastically; this study into the experiences of maternity care professionals with …
Systems pharmacology analysis of the amyloid cascade after β-secretase inhibition enables the identification of an Aβ42 oligomer pool
EMT van Maanen, TJ van Steeg, MS Michener… - … of Pharmacology and …, 2016 - ASPET
The deposition of amyloid-β (Aβ) oligomers in brain parenchyma has been implicated in the
pathophysiology of Alzheimer’s disease. Here we present a systems pharmacology model …
pathophysiology of Alzheimer’s disease. Here we present a systems pharmacology model …
[HTML][HTML] Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases
There are several antibody therapeutics in preclinical and clinical development, industry-wide,
for the treatment of central nervous system (CNS) disorders. Due to the limited …
for the treatment of central nervous system (CNS) disorders. Due to the limited …
[CITATION][C] [P2–066]: RESILIENCE MECHANISM OF THE AMYLOID PRECURSOR PROTEIN (APP) PATHWAY REVEALED BY SYSTEMS PHARMACOLOGY …
EMT van Maanen, TJ van Steeg… - Alzheimer's & …, 2017 - Wiley Online Library
Background According to the amyloid hypothesis, proteolytic processing of APP to form the β-amyloid
(Aβ) peptides plays a central role in the pathophysiology of Alzheimer's Disease (…
(Aβ) peptides plays a central role in the pathophysiology of Alzheimer's Disease (…
[CITATION][C] [P1–108]: SYSTEMS PHARMACOLOGY ANALYSIS OF THE Aβ OLIGOMER RESPONSE FOLLOWING BACE1 INHIBITION: EVIDENCE FOR SECOND …
EMT van Maanen, TJ van Steeg… - Alzheimer's & …, 2017 - Wiley Online Library
Background Toxic soluble Aβ oligomers (AβO) are considered to be primary drivers of
neurodegeneration in Alzheimer's Disease (AD). One of the main therapeutic strategies for AD is …
neurodegeneration in Alzheimer's Disease (AD). One of the main therapeutic strategies for AD is …
K24 Collaboration of occupational therapists in The Netherlands
J Heffels, M van Kampen, M van Maanen, M Clemens… - 2016 - jnnp.bmj.com
… Case history After extensive searching and comparing available communication applications,
‘Eline Speaks’ is chosen. Our choice was based on usability and extended possibilities of …
‘Eline Speaks’ is chosen. Our choice was based on usability and extended possibilities of …
[CITATION][C] P1‐276: An integrated mechanistic model to interrelate CSF Aβ40, Aβ42, sAPPβ and sAPPα response to β‐and γ‐secretase inhibitors in rhesus monkey
J Stone, E van Maanen, M Ahsman… - Alzheimer's & …, 2012 - Wiley Online Library
Background Biomarker response in cerebrospinal fluid (CSF) is commonly used to assess
response to inhibitors of brain amyloid protein (Aβ) production acting on either the β-…
response to inhibitors of brain amyloid protein (Aβ) production acting on either the β-…
Positional therapy in obstructive sleep apnea
N De Vries, M Ravesloot, JP Van Maanen - 2015 - Springer
… Peter van Maanen Department of Otolaryngology Sint Lucas Andreas Ziekenhuis … , but also
Linda Benoist, Faiza Safiruddin, Sharon Morong, Marjolein van Looij, Eline van Beest, Arjan …
Linda Benoist, Faiza Safiruddin, Sharon Morong, Marjolein van Looij, Eline van Beest, Arjan …
[HTML][HTML] Lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor shows efficacy in patients with low and intermediate-1 risk …
…, B Tanis, J Wegman, T van Maanen… - Blood, 2016 - Elsevier
Purpose: This randomized phase II study (HOVON89) in patients with low/int-1 risk MDS
refractory or unlikely to respond to erythropoietin and granulocyte-colony stimulating factor (EPO…
refractory or unlikely to respond to erythropoietin and granulocyte-colony stimulating factor (EPO…